BC Innovations | Sep 18, 2019
Distillery Therapeutics

SLC7A11 and mGluR5 identified as targets for hepatic alcoholic steatosis

DISEASE CATEGORY: Hepatic INDICATION: Liver disease Inhibiting SLC7A11, which excretes glutamate from cells, or the glutamate receptor mGluR5 could treat alcoholic steatosis of the liver. Patients with alcoholic fatty liver disease had elevated plasma levels...
BC Innovations | May 15, 2019
Distillery Therapeutics

Cystine degradation boosts immunotherapies in melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Patient sample and mouse studies suggest promoting ferroptosis by degrading cystine could enhance the efficacy of anti-PD-1 immunotherapies in melanoma. In melanoma patients, high tumor levels of SLC7A11 and SLC3A2,...
BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BC Innovations | Apr 13, 2017
Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer; cancer Cell culture and mouse studies suggest SLC7A11 inhibitors could help treat p53 -mutant esophageal cancer and other cancers that are resistant to p53 activators. In 10 p53-mutant esophageal cancer cell lines,...
BC Extra | Mar 30, 2017
Financial News

Promentis raises $26M in series C

Promentis Pharmaceuticals Inc. (Milwaukee, Wisc.) raised $26 million in a series C round led by new investors OrbiMed, F-Prime Capital and Aisling Capital . Existing investors Black Pearl GmbH, the Golden Angel Network and individual investors...
BC Innovations | Dec 10, 2015
Distillery Therapeutics

Therapeutics: Solute carrier family 7 member 11 cysteine glutamate transporter (SLC7A11; xCT)

Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest that an SLC7A11 vaccine could help treat breast cancer. Levels of SLC7A11 were higher in breast tumor samples from patients than in normal breast and...
BC Innovations | Nov 7, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Solute carrier family 7 member 11 cystine glutamate transporter (SLC7A11; xCT) In vitro and mouse studies suggest xCT inhibitors could help treat a...
BC Innovations | Feb 23, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Solute carrier family 7 member 11 cysteine glutamate transporter (SLC7A11; xCT) In vitro and mouse studies suggest the xCT inhibitor sulfasalazine...
BC Innovations | Sep 22, 2011
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Seizures Solute carrier family 7 member 11 cysteine glutamate transporter (SLC7A11; xCT) Mouse studies suggest the xCT blocker Azulfidine sulfasalazine could...
BC Innovations | May 29, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Glioma xCT In vitro and in vivo studies suggest that inhibiting the glutamate transporter xCT could be useful for treating...
Items per page:
1 - 10 of 13